Tumor necrosis factor receptor associated factor-4: An adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2963-2968

  Ahmed, Fozia ^a,b   Shiraishi, Takumi ^a,c   Vessella, Robert L ^d   Kulkarni, Prakash ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Metastatic prostate cancer; microRNA 29a; Tumor necrosis factor receptor associated factor 4

Indexed keywords

MICRORNA 29A; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SOFT TISSUE METASTASIS; UPREGULATION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 4; TRANSCRIPTIONAL ACTIVATION;

EID: 84892422964     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2789     Document Type: Article

References (35)

1. Chung JY, Park YC, Ye H and Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115: 679-688, 2002.
2. Rothe M, Wong SC, Henzel WJ and Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78: 681-692, 1994.
3. Xie P: TRAF molecules in cell signaling and in human diseases. J Mol Signal 8: 7, 2013.
4. Regnier CH, Tomasetto C, Moog-Lutz C, et al: Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 270: 25715-25721, 1995.
5. Camilleri-Broet S, Cremer I, Marmey B, et al: TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26: 142-147, 2007.
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065, 2006.
8. El Baroudi M, Cora D, Bosia C, Osella M and Caselle M: A curated database of miRNA mediated feed-forward loops involving MYC as master regulator. PLoS One 6: e14742, 2011.
9. Hermeking H: p53 enters the microRNA world. Cancer Cell 12: 414-418, 2007.
10. Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199, 2010.
11. Kole AJ, Swahari V, Hammond SM and Deshmukh M: miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev 25: 125-130, 2011.
12. Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 α and CDC42. Nat Struct Mol Biol 16: 23-29, 2009.
13. Fabbri M, Garzon R, Cimmino A, et al: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810, 2007.
14. Garzon R, Heaphy CE, Havelange V, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341, 2009.
15. Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140, 2007.
16. Sengupta S, den Boon JA, Chen IH, et al: MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105: 5874-5878, 2008.
17. Xiong Y, Fang JH, Yun JP, et al: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845, 2010.
18. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007.
19. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell 115: 787-798, 2003.
20. Shiraishi T, Terada N, Zeng Y, et al: Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 9: 153, 2011.
21. Yoshida T, Shiraishi T, Horinaka M, et al: Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 98: 1417-1423, 2007.
22. Kedinger V and Rio MC: TRAF4, the unique family member. Adv Exp Med Biol 597: 60-71, 2007.
23. Kalkan T, Iwasaki Y, Park CY and Thomsen GH: Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-β signaling that affects neural crest formation. Mol Biol Cell 20: 3436-3450, 2009.
24. Ye L, Lewis-Russell JM, Kyanaston HG and Jiang WG: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 22: 1129-1147, 2007.
25. Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000.
26. Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
27. Ellwood-Yen K, Graeber TG, Wongvipat J, et al: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238, 2003.
28. Hawksworth D, Ravindranath L, Chen Y, et al: Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13: 311-315, 2010.
29. Jenkins RB, Qian J, Lieber MM and Bostwick DG: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: 524-531, 1997.
30. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441: 431-436, 2006.
31. Ismail HA, Lessard L, Mes-Masson AM and Saad F: Expression of NF-κB in prostate cancer lymph node metastases. Prostate 58: 308-313, 2004.
32. Lessard L, Begin LR, Gleave ME, Mes-Masson AM and Saad F: Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93: 1019-1023, 2005.
33. Lessard L, Karakiewicz PI, Bellon-Gagnon P, et al: Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 12: 5741-5745, 2006.
34. Setlur SR, Royce TE, Sboner A, et al: Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67: 10296-10303, 2007.
35. Esparza EM and Arch RH: TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation. Cell Mol Life Sci 61: 3087-3092, 2004.